Fig. 1.
Total volumes of distribution (V T) of [18F]-FEPPA in each of the studied ROIs (hippocampus; mPFC, medial prefrontal cortex; temporal cortex; DLPFC, dorsolateral PFC; and striatum). Data are presented as partial volumes uncorrected VTs (A) and partial volume effect-corrected VTs (B). No significant effect of clinical group (HV vs SCZ) was detected on [18F]-FEPPA VTs when controlling for genetics (F (1,39) = 0.179, P = .674). These findings were unchanged following correction for partial volume effects (F (1,39) = 0.401, P = .530). [18F]-FEPPA, N-acetyl-N-(2-[18F]fluoroethoxybenzyl)-2-phenoxy-5-pyridinamine; HV, healthy volunteer; ROI, regions of interest; SCZ, schizophrenia.